Preeya K Gupta, Vance Thompson, Leslie O'Dell, Anh N Ho, Arthur Chan, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu
{"title":"Patient-Reported Burden of Illness and Unmet Needs in <i>Demodex</i> blepharitis.","authors":"Preeya K Gupta, Vance Thompson, Leslie O'Dell, Anh N Ho, Arthur Chan, Bhagyashree Oak, Amod Athavale, Elizabeth Yeu","doi":"10.2147/PPA.S501764","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong><i>Demodex</i> blepharitis is an ocular disorder caused by the infestation of <i>Demodex</i> mites that reside on the eyelash follicles.</p><p><strong>Objective: </strong>This study assessed the clinical, humanistic, and economic burden of <i>Demodex</i> blepharitis from a patient perspective.</p><p><strong>Methods: </strong>This cross-sectional, observational study used a web-enabled survey to collect data from US adults with <i>Demodex</i> blepharitis in 2022. Patients with unique burdens, including those receiving dry eye disease medications, wearing contact lenses, or experiencing cataracts or glaucoma were also examined.</p><p><strong>Results: </strong>Among 113 patients, mean age was 48.5 years (standard deviation [SD] ± 13.6). Half had private/commercial insurance, and 55% had Medicare and/or Medicaid. Patients had <i>Demodex</i> blepharitis for an average of 4.3 years (SD ± 6.7 years) before the study, and 1.2 years (SD ± 3.0 years) elapsed between the appearance of symptoms and diagnosis. Common symptoms, including redness, dryness, itchiness of the eyelids, and itchiness of the eyes, persisted or returned shortly after diagnosis and disease management in most patients, and they were associated with a negative impact on quality of life. Patients visited their healthcare practitioner for <i>Demodex</i> blepharitis a mean of 3.9 times (SD ± 4.8) in the preceding year. Patients were often managed with off-label prescription medications, such as medications indicated for dry eye disease, in-office procedures, or over-the-counter management options.</p><p><strong>Discussion: </strong>Patients with <i>Demodex</i> blepharitis reported symptoms impacting their quality of life and activities of daily living, which persisted after diagnosis and disease management. This suggested that the effectiveness of the reported symptom management options was temporary and highlighted an unmet need in treating the root cause of the disease.</p><p><strong>Conclusion: </strong>Patients with <i>Demodex</i> blepharitis were symptomatic, and the commonly used management options for <i>Demodex</i> blepharitis lacked long-term symptom relief or mite eradication, demonstrating a high unmet need in treating patients with <i>Demodex</i> blepharitis.</p>","PeriodicalId":19972,"journal":{"name":"Patient preference and adherence","volume":"19 ","pages":"647-658"},"PeriodicalIF":2.0000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11929423/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient preference and adherence","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/PPA.S501764","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Demodex blepharitis is an ocular disorder caused by the infestation of Demodex mites that reside on the eyelash follicles.
Objective: This study assessed the clinical, humanistic, and economic burden of Demodex blepharitis from a patient perspective.
Methods: This cross-sectional, observational study used a web-enabled survey to collect data from US adults with Demodex blepharitis in 2022. Patients with unique burdens, including those receiving dry eye disease medications, wearing contact lenses, or experiencing cataracts or glaucoma were also examined.
Results: Among 113 patients, mean age was 48.5 years (standard deviation [SD] ± 13.6). Half had private/commercial insurance, and 55% had Medicare and/or Medicaid. Patients had Demodex blepharitis for an average of 4.3 years (SD ± 6.7 years) before the study, and 1.2 years (SD ± 3.0 years) elapsed between the appearance of symptoms and diagnosis. Common symptoms, including redness, dryness, itchiness of the eyelids, and itchiness of the eyes, persisted or returned shortly after diagnosis and disease management in most patients, and they were associated with a negative impact on quality of life. Patients visited their healthcare practitioner for Demodex blepharitis a mean of 3.9 times (SD ± 4.8) in the preceding year. Patients were often managed with off-label prescription medications, such as medications indicated for dry eye disease, in-office procedures, or over-the-counter management options.
Discussion: Patients with Demodex blepharitis reported symptoms impacting their quality of life and activities of daily living, which persisted after diagnosis and disease management. This suggested that the effectiveness of the reported symptom management options was temporary and highlighted an unmet need in treating the root cause of the disease.
Conclusion: Patients with Demodex blepharitis were symptomatic, and the commonly used management options for Demodex blepharitis lacked long-term symptom relief or mite eradication, demonstrating a high unmet need in treating patients with Demodex blepharitis.
期刊介绍:
Patient Preference and Adherence is an international, peer reviewed, open access journal that focuses on the growing importance of patient preference and adherence throughout the therapeutic continuum. The journal is characterized by the rapid reporting of reviews, original research, modeling and clinical studies across all therapeutic areas. Patient satisfaction, acceptability, quality of life, compliance, persistence and their role in developing new therapeutic modalities and compounds to optimize clinical outcomes for existing disease states are major areas of interest for the journal.
As of 1st April 2019, Patient Preference and Adherence will no longer consider meta-analyses for publication.